InVision Medical Technology

AI Echocardiography Interpretation and Diagnosis.
Backed by @YCombinator
.

[InVision Medical Technology @InVision_AI]

InVision is excited to announce that Andrew Reeve has joined as Chief Commercial Officer. Andrew will build the health-system partnerships that bring InVision's cleared cardiac AI to every echocardiography lab.

Andrew will be at #ASE2026 in Denver! Please say hi!

[InVision Medical Technology @InVision_AI]

@Dandelion_AI4H https://t.co/TFRGbyNQKg

[InVision Medical Technology @InVision_AI]

We are excited to partner with the @Dandelion_AI4H team for precision phenotyping in real world evidence.

State of the art AI echo enhances the rich multimodal clinical data in Dandelion's marketplace for deep understanding of cardiometabolic disease.

[InVision Medical Technology @InVision_AI]

https://t.co/sZU01mdgNe

[InVision Medical Technology @InVision_AI]

Introducing our new webpage as we introduce the InVision Precision Platform, automating interpretation, measurement, and disease detection.

Contact us for a demo!

[InVision Medical Technology @InVision_AI]

We are excited to announce that InVision has received Breakthrough Device Designation from the US FDA for AI enabled liver disease detection from routine echocardiography.

https://t.co/lkkXTpfFpt

[InVision Medical Technology @InVision_AI]

More information here: https://t.co/kCJuKnMpjz

[InVision Medical Technology @InVision_AI]

Excited to work with @heartlabnz to bring rare disease and heart failure diagnostics to Australia and New Zealand! They are a fantastic partner in advancing cardiovascular imaging!

[David Ouyang, MD @David_Ouyang]

We are excited to announce that both EchoPrime @milos_ai and EchoNet-Measurements @Yuki_Sahashi will be presented at the @ASE360 Scientific Sessions Late Breaking Science session!

See you in September at #ASE2025 in Nashville!

[InVision Medical Technology @InVision_AI]

InVision Precision Cardiac Amyloid receives FDA clearance. Previously receiving Breakthrough Designation, InVision PCA is an AI-#echofirst algorithm for the detection of AL and ATTR Cardiac Amyloidosis

https://t.co/lY388CmJkw

[David Ouyang, MD @David_Ouyang]

1/n We are excited to announce EchoPrime – the first echocardiography AI model capable of evaluating a full transthoracic echocardiogram study, identify the most relevant videos, and produce a comprehensive interpretation!

Great work lead by @milos_ai, EchoPrime is the largest and most complex #echofirst AI model yet, trained on 10x the data of existing models.

[InVision Medical Technology @InVision_AI]

Congratulations to the HELIOS-B investigators!

Early recognition of TTR amyloidosis leads to the most effective treatment of this deadly disease. Initiation of therapy at earlier stages lead to an even more dramatic impact on survival and decrease in cardiovascular events!

[Ronald Witteles @Ron_Witteles]

The results hold nicely across all of the prespecified subgroups. Perhaps the most interesting point here is something that has been seen in other amyloidosis trials as well: there appears to be a larger treatment effect for those diagnosed earlier (NTBNP < or > 2000).

[InVision Medical Technology @InVision_AI]

We are excited to announce a new CPT code for AI-enhanced echo for detection of Cardiac Amyloidosis! Yesterday, the AMA has issued new CPT code 0932T, a new Cat 3 CPT code to track InVision Precision Cardiac Amyloid usage starting 1/1/2025.

https://t.co/EbVSgeut9t

[InVision Medical Technology @InVision_AI]

Thanks for highlighting our FDA clearance! We are excited to be the only echo AI tested in prospective RCT!

[Cardiac Wire @Cardiac_Wire]

The FDA published its latest Healthcare AI Database last week, featuring a massive 882 AI-enabled medical device clearances, and highlighting some interesting trends in cardiovascular AI.
https://t.co/NBku5zvJ5k

[InVision Medical Technology @InVision_AI]

We are proud to announce the FDA 510k clearance of Precision LVEF - the only AI-LVEF algorithm proven to provide time savings and improve clinician accuracy in blinded randomized clinical trial!

https://t.co/w34iyFNyOQ

[InVision Medical Technology @InVision_AI]

@InVision_AI is excited to participate in the @US_FDA's Total Product Life Cycle Advisory Program.

We are excited to work with CRDH and OHT2 to evaluate InVision Cardiac Amyloidosis Screening.

Our goal is to develop high-quality, safe, effective SaMD medical devices.

[David Ouyang, MD @David_Ouyang]

We are thrilled to be funded by the @MooreFound and @KPDOR's AIM-HI initiative to study the deployment of AI to screen for cardiac amyloidosis working with an excellent team of physician scientists across four diverse sites.

@Paul_P_Cheng @tygluckman @FarazAhmadMD

@SmidtHeart @VAPaloAlto @providence @NorthwesternMed

[InVision Medical Technology @InVision_AI]

We are excited to announce InVision has secured FDA breakthrough device designation for #ai enabled #amyloidosis detection. The AI algorithm integrates information from multiple #echofirst views and is the only peer reviewed algorithm of its kind.

https://t.co/2s3NCLSDVa

[InVision Medical Technology @InVision_AI]

We are excited to partner with @AlexionPharma to improve diagnosis of rare diseases, such as cardiac amyloidosis.

Artificial intelligence can both improve speed and precision of diagnosis.

https://t.co/PWbs0vsISB

@AlexionPharmaUS @AstraZeneca @Amyloidosis_ARC

[InVision Medical Technology @InVision_AI]

@SiemensHealth @Philips @ASCENDCV @heartlabnz @ButterflyNetInc @kosmos_echonous @UltraSightAI @David_Ouyang @bryandhe @james_y_zou @escardio @Nature Check out our demo at https://t.co/l7A6ZYhI5z!

#AHA2023 @ASE360

5/5

[InVision Medical Technology @InVision_AI]

Hey #AHA23! We are excited to announce @InVision_AI Precision, our automated AI echocardiography solution! Our model is the first and only AI #echofirst model that has shown superiority in a prospective, blinded RCT.

1/5

[InVision Medical Technology @InVision_AI]

@SiemensHealth @Philips @ASCENDCV @heartlabnz @ButterflyNetInc @kosmos_echonous @UltraSightAI @David_Ouyang @bryandhe @james_y_zou The only blinded RCT of #echofirst AI, @InVision_AI Precision saved cardiologists time and required less changing in head-to-head comparison with experienced sonographers. The results were presented at @escardio 2022 and published @Nature 2023.

https://t.co/F2oZqxrypX

4/5

[David Ouyang, MD @David_Ouyang]

We are excited to announce that our blinded randomized clinical trial of AI LVEF (EchoNet-Dynamic) has been published in @nature! @bryandhe @james_y_zou @StanfordDBDS @CedarsSinaiMed

https://t.co/n7ntvPELUm

1/n